Innovent Biologics, Inc.

Established in 2011 and based in Suzhou, China, Innovent Biologics, Inc. is a biopharmaceutical company that engages in the development, manufacturing, and commercialization of new drugs for cancers. In October 2018, it was listed on the Hong Kong Stock Exchange under the number 01801. In December 2024, Innovent Biologics, Inc.

raised an undisclosed amount of venture funding from new investor Xuhui Science and Technology Venture Capital. It has multiple branches in Suzhou, Shanghai, Beijing, and overseas USA and Europe. Innovent Biologics, Inc. provides 35 monoclonal antibody drugs for cancer, immunity, and metabolic disease.

It has eight products that were approved for marketing, and its product trademarks include TYVYT®, BYVASDA®, SULINNO®, HALPRYZA®, EMAZYRE®, and CYRAMZA®. It has 3 drugs in the NMPA review phase, 5 drugs are in the three-phase clinical trials, and the other 19 new drugs are in clinical research and development. Innovent Biologics, Inc. plans to promote lung cancer drugs IBI-351 (KRASG12C) and IBI-344 (ROS1/TRK) clinical registration and submit a new drug application (NDA) by the end of 2023.

ADC molecular drugs will enter into the first phase of clinical trials. Besides, it also focuses on the fields of cardiovascular and metabolic, autoimmune, and ophthalmology. And obesity diabetes drug IBI-362, Tao drug IBI-311 will be in the third phase of registration clinical, and gout drug IBI-128 will be in the third phase of clinical trials by the end of 2023.